The effect of montelukast therapy on messenger ribonucleic acid (mRNA) profile of matrix metalloproteinases and their inhibitors in the sputum of patients with asthma

niversity of East Anglia (UK)0 个研究点目标入组 10 人开始时间: 2009年6月17日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Male or female, aged 18 to 60 years
•2. Diagnosed with asthma, defined as episodic chest tightness, wheezing and dyspnoea, cough
•3. Non-smoker or ex-smoker for at least 10 years and a smoking history of less than 5 pack years
•4. History of asthma symptoms for more than 10 years
•5. Receiving as required short acting bronchodilators
•6. Post-bronchodilator forced expiratory volume in one second (FEV1) 50 - 100% predicted
•7. Evidence of airway calibre reversibility within the previous 12 months: reversibility to salbutamol of 12% following 400 µg inhaled salbutamol, histamine PC20 less than 8 mg/ml, diurnal variation in peak expiratory flow of 20%
•8. Able to produce sputum after induction with saline

•1. Cardiac or pulmonary disease other than asthma
•2. Respiratory infection defined as fever, nasal/sinus congestion, fatigue, cough, antibiotic use or yellow/green sputum within 4 weeks prior to study
•3. Receiving inhaled or oral corticosteroid therapy, long acting ?Ò2 agonist therapy or leukotriene modifying therapy for the previous 1 month
•4. Severe or uncontrolled co-morbid disease
•5. Pregnancy or breastfeeding
•6. Unable to give written informed consent

发起方

niversity of East Anglia (UK)